Sanjana Ballal

Broadening horizons with 225Ac-DOTATATE targeted alpha therapy for gastroenteropancreatic neuroendocrine tumour patients stable or refractory to 177Lu-DOTATATE PRRT: first clinical experience on the efficacy and safety

Sanjana Ballal, Madhav Prasad Yadav, Chandrasekhar Bal et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2019 · 210 citations

Medicine, Nuclear Medicine, Oncology +17

Efficacy and safety of ²²⁵Ac-PSMA-617 targeted alpha therapy in metastatic castration-resistant Prostate Cancer patients

Madhav Prasad Yadav, Sanjana Ballal, Ranjit Kumar Sahoo et al. · Theranostics · 2020 · 153 citations · Full text

Medicine, Oncology, Pharmacology +17

Biodistribution, pharmacokinetics, dosimetry of [68Ga]Ga-DOTA.SA.FAPi, and the head-to-head comparison with [18F]F-FDG PET/CT in patients with various cancers

Sanjana Ballal, Madhav Prasad Yadav, Euy Sung Moon et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2020 · 153 citations

Medicine, Nuclear Medicine, Radiology +12

177Lu-DKFZ-PSMA-617 therapy in metastatic castration resistant prostate cancer: safety, efficacy, and quality of life assessment

Madhav Prasad Yadav, Sanjana Ballal, Madhavi Tripathi et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2016 · 146 citations

Medicine, Oncology, Pharmacology +16

First-In-Human Results on the Biodistribution, Pharmacokinetics, and Dosimetry of [177Lu]Lu-DOTA.SA.FAPi and [177Lu]Lu-DOTAGA.(SA.FAPi)2

Sanjana Ballal, Madhav Prasad Yadav, Euy Sung Moon et al. · Pharmaceuticals · 2021 · 128 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +9